Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2009

01.09.2009 | Endocrine Tumors

High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma

verfasst von: Jen-Der Lin, MD, Tzu-Chieh Chao, MD, PhD, Chuen Hsueh, MD, Sheng-Fong Kuo, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Multicentric papillary thyroid carcinoma (PTC) is not unusual in patients with PTC. However, its clinical features concerning cancer recurrence and mortality are not well described.

Methods

A total of 1682 PTC patients at a single institution who underwent total thyroidectomy were retrospectively reviewed; the mean follow-up period was 7.7 ± 0.1 years. Postoperative radioactive iodide ablation for thyroid remnant was performed after surgery for most patients.

Results

Of all the PTC cases reviewed, 337 cases (20.0%) were categorized as multicentric PTC. Compared with patients with unifocal PTC, multicentric PTC patients demonstrated older age, advanced TNM staging, and higher recurrence. A higher recurrence rate for multicentric PTC (20.2%) was observed compared with that for unifocal PTC; 45.8% of multicentric PTC cases with ≥ 5 foci experienced cancer recurrence. Mean tumor size of the largest nodule in patients with multicentric PTC was significantly smaller than that found in unifocal PTC. Patients with multicentric papillary microcarcinoma (≤1 cm) had higher recurrence rate and cancer mortality than those with unifocal papillary microcarcinoma. Of the recurrent multicentric PTC cases, 52.9% were persistent or diagnosed within the first year of thyroidectomy and had a cancer-related mortality of 27.8%. The 5-, 10-, and 20-year survival rates of multicentric PTC patients were 97.7%, 94.4%, and 84.7%, respectively, which were not statistically different from those of unifocal PTC patients.

Conclusions

Multicentric PTC warrant postoperative adjuvant therapy and close surveillance within the first year. Patients with multicentric papillary thyroid microcarcinoma need to be treated as high-risk patients.
Literatur
1.
Zurück zum Zitat Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273–80.PubMedCrossRef Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273–80.PubMedCrossRef
2.
Zurück zum Zitat Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol. 2006;13:1524–8.PubMedCrossRef Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol. 2006;13:1524–8.PubMedCrossRef
3.
Zurück zum Zitat Low TH, Delbridge L, Sidhu S, Learoyd D, Robinson B, Roach P, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827–32.PubMedCrossRef Low TH, Delbridge L, Sidhu S, Learoyd D, Robinson B, Roach P, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827–32.PubMedCrossRef
4.
Zurück zum Zitat Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al. The heterogenous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3511–6.PubMedCrossRef Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al. The heterogenous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3511–6.PubMedCrossRef
5.
Zurück zum Zitat Sobin LH, UICC (2002) Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52–6. Sobin LH, UICC (2002) Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52–6.
6.
Zurück zum Zitat Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92.PubMedCrossRef Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92.PubMedCrossRef
7.
Zurück zum Zitat Delellis RA, Lloyd RV, Heitx PU, Eng C. Pathology and genetics of tumors of endocrine organs. In: World health organization of tumours. Lyon: IARC; 2004. p. 73–6. Delellis RA, Lloyd RV, Heitx PU, Eng C. Pathology and genetics of tumors of endocrine organs. In: World health organization of tumours. Lyon: IARC; 2004. p. 73–6.
8.
Zurück zum Zitat Zhang DD, Zhou XH, Freeman DH, Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701–15.PubMedCrossRef Zhang DD, Zhou XH, Freeman DH, Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701–15.PubMedCrossRef
9.
Zurück zum Zitat Simonowitz D, Thomsen S, Moossa AR, Block GE. The treatment of incidental papillary thyroid cancer. Arch Surg. 1976;111:477–83.PubMed Simonowitz D, Thomsen S, Moossa AR, Block GE. The treatment of incidental papillary thyroid cancer. Arch Surg. 1976;111:477–83.PubMed
10.
Zurück zum Zitat Miyaki M, Iijima T, Ishii R, Hishima T, Mori T, Yoshinaga K, et al. Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis. Am J Pathol. 2000;157:1825–7.PubMed Miyaki M, Iijima T, Ishii R, Hishima T, Mori T, Yoshinaga K, et al. Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis. Am J Pathol. 2000;157:1825–7.PubMed
11.
Zurück zum Zitat Gerfo PL, Chabot J, Gazetas P. The intraoperative incidence of detectable bilateral and multicentric disease in papillary cancer of the thyroid. Surgery. 1990;108:958–62.PubMed Gerfo PL, Chabot J, Gazetas P. The intraoperative incidence of detectable bilateral and multicentric disease in papillary cancer of the thyroid. Surgery. 1990;108:958–62.PubMed
12.
13.
Zurück zum Zitat Stoffer SS, Van Dyke DL, Bach JV, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986;25:775–82.PubMedCrossRef Stoffer SS, Van Dyke DL, Bach JV, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986;25:775–82.PubMedCrossRef
14.
Zurück zum Zitat Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173–9.PubMedCrossRef Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173–9.PubMedCrossRef
15.
Zurück zum Zitat Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, et al. Geographic mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer. 2008;7:89.PubMedCrossRef Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, et al. Geographic mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer. 2008;7:89.PubMedCrossRef
16.
Zurück zum Zitat Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutation status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol. 2009;16:240–5.PubMedCrossRef Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutation status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol. 2009;16:240–5.PubMedCrossRef
17.
Zurück zum Zitat Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–90.PubMedCrossRef Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–90.PubMedCrossRef
18.
Zurück zum Zitat Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, et al. BRAF (V600E) mutation and p27 (kip1) expression in papillary carcinomas of the thyroid </=1 cm and their paired lymph node metastases. Cancer. 2007;110:1218–26.PubMedCrossRef Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, et al. BRAF (V600E) mutation and p27 (kip1) expression in papillary carcinomas of the thyroid </=1 cm and their paired lymph node metastases. Cancer. 2007;110:1218–26.PubMedCrossRef
19.
Zurück zum Zitat Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol. 2005;63:588–93.CrossRef Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol. 2005;63:588–93.CrossRef
20.
Zurück zum Zitat Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–95.PubMedCrossRef Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–95.PubMedCrossRef
21.
Zurück zum Zitat Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022–9.PubMedCrossRef Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022–9.PubMedCrossRef
22.
Zurück zum Zitat Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319–25.PubMedCrossRef Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319–25.PubMedCrossRef
23.
Zurück zum Zitat Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo A, Foletto M, et al. Complications in thyroid surgery for carcinoma: one institution’s surgical experience. World J Surg. 2008;32:572–5.PubMedCrossRef Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo A, Foletto M, et al. Complications in thyroid surgery for carcinoma: one institution’s surgical experience. World J Surg. 2008;32:572–5.PubMedCrossRef
24.
Zurück zum Zitat Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–94.PubMedCrossRef Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–94.PubMedCrossRef
25.
Zurück zum Zitat Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, Broelsch CE. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 2000;128:1067–74.PubMedCrossRef Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, Broelsch CE. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 2000;128:1067–74.PubMedCrossRef
26.
Zurück zum Zitat Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11.PubMedCrossRef Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11.PubMedCrossRef
27.
Zurück zum Zitat Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med. 2005;43:843–7.PubMedCrossRef Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med. 2005;43:843–7.PubMedCrossRef
28.
Zurück zum Zitat Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.PubMedCrossRef Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.PubMedCrossRef
29.
Zurück zum Zitat Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, et al. Outcome predictors and impact of central node dissection and radiometabolic treatment in papillary thyroid cancers <=2 cm. Endocr Relat Cancer. 2009;16:201–10.PubMedCrossRef Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, et al. Outcome predictors and impact of central node dissection and radiometabolic treatment in papillary thyroid cancers <=2 cm. Endocr Relat Cancer. 2009;16:201–10.PubMedCrossRef
30.
Zurück zum Zitat Noguchi S, Yamashita H, Uchino S. Modified radical neck dissection is better than partial dissection of lymph nodes. World J Surg. 2009;33:394–6.PubMedCrossRef Noguchi S, Yamashita H, Uchino S. Modified radical neck dissection is better than partial dissection of lymph nodes. World J Surg. 2009;33:394–6.PubMedCrossRef
Metadaten
Titel
High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma
verfasst von
Jen-Der Lin, MD
Tzu-Chieh Chao, MD, PhD
Chuen Hsueh, MD
Sheng-Fong Kuo, MD
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0565-7

Weitere Artikel der Ausgabe 9/2009

Annals of Surgical Oncology 9/2009 Zur Ausgabe

Hepatobiliary and Pancreatic Tumors

Timing Means Everything, Maybe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.